D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia

计划入组 52 人 · 首次发布于 2009 年 8 月 17 日

Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration

计划入组 20 人 · 首次发布于 2016 年 3 月 23 日

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

计划入组 60 人 · 首次发布于 2013 年 7 月 25 日

DAAO inhibitors (Eisai)

RS-D7 prodrug

AS-057278

Shanghai Ajinomoto Amino Acid Co., Ltd.

China

AMINO GmbH

Germany

Anabio R&D

Vietnam

Dasher Neuroscience Completes Patient Enrollment in Phase 2 Trial of YA-101 for Multiple System Atrophy

Two Phase 2 Trials Fail to Demonstrate Cognitive Benefits in Schizophrenia Despite Different Mechanisms

Neurocrine's Luvadaxistat Fails Phase II Trial for Cognitive Impairment in Schizophrenia